The Dual Peroxisome Proliferator-Activated Receptor α/γ Activator Muraglitazar Prevents the Natural Progression of Diabetes in db/db Mice
Authors:
- Randolph PonticielloRPRandolph Ponticiello
- JoAnn SwartzJSJoAnn Swartz
- Dennis FarrellyDFDennis Farrelly
- Rachel ZeboRZRachel Zebo
- Gustav WelzelGWGustav Welzel
- Donald EganDEDonald Egan
- Lori KunselmanLKLori Kunselman
- Andrew PetersAPAndrew Peters
- Liqun GuLGLiqun Gu
- Michele FrenchMFMichele French
- Sean ChenSCSean Chen
- 1 April 2007
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 321 (1) , 107-115
Abstract
There are two major defects in type 2 diabetes: 1) insulin resistance and 2) insulin deficiency due to loss of β-cell function. Here we demonstrated that treatment with muraglitazar (a dual peroxisome proliferator-activated receptor α/γ activator), when initiated before or after the onset of diabetes in mice, is effective against both defects. In study 1, prediabetic db/db mice were treated for 12 weeks. The control mice developed diabetes, as evidenced by hyperglycemia, hyperinsulinemia, reduced insulin levels in the pancreas, blunted insulin response to glucose, and impaired glucose tolerance. The muraglitazar-treated mice had normal plasma glucose, and insulin levels, equivalent or higher pancreatic insulin content than normal mice, showed a robust insulin response to glucose and exhibited greater glucose tolerance. In study 2, diabetic db/db mice were treated for 4 weeks. The control mice displayed increased glucose levels, severe loss of islets, and their isolated islets secreted reduced amounts of insulin in response to glucose and exendin-4 compared with baseline. In muraglitazar-treated mice, glucose levels were reduced to normal. These mice showed reduced loss of islets, and their isolated islets secreted insulin at levels comparable to baseline. Thus, muraglitazar treatment decreased both insulin resistance and preserved β-cell function. As a result, muraglitazar treatment, when initiated before the onset of diabetes, prevented development of diabetes and, when initiated after the onset of diabetes, prevented worsening of diabetes in db/db mice.Keywords
This publication has 37 references indexed in Scilit:
- Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study dataInternational Journal Of Clinical Practice, 2006
- The Natural Course of β-Cell Function in Nondiabetic and Diabetic IndividualsDiabetes, 2006
- Muraglitazar, a Novel Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, Improves Diabetes and Other Metabolic Abnormalities and Preserves β-Cell Function in db/db MiceDiabetes, 2006
- Multifaceted Therapeutic Approaches for a Multigenic DiseaseDiabetes, 2005
- Mechanisms of Pancreatic β-Cell Death in Type 1 and Type 2 DiabetesDiabetes, 2005
- Non-Insulin Dependent Diabetes Mellitus: Present Therapies and New Drug TargetsMini-Reviews in Medicinal Chemistry, 2005
- Design and Synthesis of N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering ActivitiesJournal of Medicinal Chemistry, 2004
- Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic WomenDiabetes, 2002
- The Prevention or Delay of Type 2 DiabetesDiabetes Care, 2002
- Free Fatty Acids and Pathogenesis of Type 2 Diabetes MellitusTrends in Endocrinology & Metabolism, 2000